[Federal Register Volume 82, Number 135 (Monday, July 17, 2017)]
[Pages 32713-32714]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14861]



National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.


SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Dr. Peter Tung; 240-669-5483; 
[email protected]. Licensing information and copies of the patent 
applications listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Compounds That Treat Malaria and Prevent Malaria Transmission

Description of Technology

    Malaria is the single leading cause of death, especially among 
children, in the developing world. Malaria is caused by infection with 
parasites of the genus Plasmodium, transmitted by mosquitos. In 
addition to transmission, vital steps in the parasite lifecycle occur 
in the mosquito host. The invention offered for licensing relates to 
therapeutic compounds and related pharmaceutical compositions that can 
be used in the prevention and treatment of malaria infection. More 
specifically, the invention is drawn to compounds that may kill sexual 
and mosquito stage malaria parasites to block transmission. 
Specifically claimed is the antihistamine Ketotifen, which has 
demonstrated activity blocking parasite development in mosquitoes. Also 
claimed are treatments encompassing Ketotifen with other existing 
antimalarial drugs in a combination treatment aimed at multiple stages 
in the malaria life cycle.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 

Potential Commercial Applications

 Prevention and treatment of malaria infections

Competitive Advantages

     Drugs that kill sexual and mosquito stages of the parasite 
are important for preventing and/or slowing the spread of malaria 
infection and ultimately for malaria eradication.
     Primaquine, the only currently available drug shown to 
block transmission, is known to cause serious adverse side effects.

Development Stage

 Pre-Clinical (animal data available)

    Inventors: Xin-zhuan Su and Dipak Raj (NIAID).
    Publications: Eastman R.T. Pattaradilokrat S. Raj D.K. Dixit S. 
Deng B. Miura K. Yuan J. Tanaka T.Q. Johnson R.L. Jiang H. et al. 2013. 
A class

[[Page 32714]]

of tricyclic compounds blocking malaria parasite oocyst development and 
transmission. Antimicrob. Agents Chemother. 57: 425-435.
    Intellectual Property: US Patent # 9,375,424, US divisional patent 
application: 13/392,668, Worldwide patent applications: Canada 2772085, 
Europe 10812670.7, India 1684/DELNP/2012. Priority Application 61/
237,417 filed August 27, 2009. (HHS Reference No. E-283-2009)
    Licensing Contact: Peter Tung, Ph.D.; 240-669-5483; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact Peter Tung; 240-669-5483; 
[email protected].

    Dated: July 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-14861 Filed 7-14-17; 8:45 am]